Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

OGN.US - Current Price

$8.12

Company Information

Company Name
Organon & Co
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYSE
ISIN: US68622V1061
CIK: 0001821825
CUSIP: 68622V106
Currency: USD
Full Time Employees: 10,000
Phone: 551 430 6900
Fiscal Year End: December
IPO Date: Jun 02, 2021
Description:

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Address:

30 Hudson Street, Jersey City, NJ, United States, 07302

Directors & Officers

Name Title Year Born
Ms. Carrie Smith Cox Executive Chairman of the Board 1959
Mr. Joseph T. Morrissey Jr. Interim CEO & Executive VP and Head of Manufacturing & Supply 1965
Mr. Matthew M. Walsh C.F.A. Executive VP & CFO 1967
Dr. Juan Camilo Arjona Ferreira M.D. Executive VP, Head of Research & Development and Chief Medical Officer 1971
Ms. Jennifer Halchak Head of Investor Relations NA
Mr. Kirke Weaver Executive VP, General Counsel & Corporate Secretary 1973
Mr. Daniel Karp Head of Corporate Development 1978
Mr. Aaron Falcione Executive VP & Chief Human Resources Officer 1971
Mr. Vittorio Nisita Executive VP & Head of Enterprise Services and Solutions 1968
Ms. Rachel A. Stahler Chief Digital & Growth Officer 1976

Shares Statistics

Shares Outstanding: 259.98M
Shares Float: 258.72M
% Insiders: 25.60%
% Institutions: 7,828.00%
Short % Float: 8.51%

Valuation Metrics

Enterprise Value: $10.25B
Trailing P/E: 4.21
Forward P/E: 5.03

Financial Highlights

Market Cap: $2.09B
EBITDA: $1.69B
P/E Ratio: $4.21
Book Value: $3.49
Dividend/Share: $0.60
Dividend Yield: 8.06%
Earnings/Share: $1.91
Profit Margin: 7.95%
Operating Margin: 23.10%
ROA (TTM): 6.40%
ROE (TTM): 71.62%
Revenue (TTM): $6.30B
Revenue/Share (TTM): $24.34
Earnings Growth (YOY): -55.80%
Revenue Growth (YOY): 1.30%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

Date EPS Actual EPS Estimate Difference Surprise %
Sep 30, 2025 1.01 0.93 N/A 860.22%
Jun 30, 2025 1.00 0.94 N/A 638.30%
Mar 31, 2025 1.02 0.89 N/A 1,460.67%
Dec 31, 2024 0.90 0.87 N/A 344.83%
Sep 30, 2024 0.87 0.90 N/A -333.33%
Jun 30, 2024 1.12 1.08 N/A 370.37%
Mar 31, 2024 1.22 0.97 N/A 2,577.32%
Dec 31, 2023 0.88 0.83 N/A 602.41%
Sep 30, 2023 0.87 1.06 N/A -1,792.45%
Jun 30, 2023 1.31 1.01 N/A 2,970.30%
Mar 31, 2023 1.08 1.16 N/A -689.66%
Dec 31, 2022 0.81 0.90 N/A -1,000.00%
Sep 30, 2022 1.32 1.09 N/A 2,110.09%
Jun 30, 2022 1.25 1.16 N/A 775.86%
Mar 31, 2022 1.65 1.30 N/A 2,692.31%
Dec 31, 2021 1.37 1.24 N/A 1,048.39%
Sep 30, 2021 1.67 1.44 N/A 1,597.22%
Jun 30, 2021 1.72 1.40 N/A 2,285.71%
Mar 31, 2021 1.58 1.52 N/A 394.74%

Balance Sheet (Yearly)

Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $675.00M $N/A $13.10B $12.63B $472.00M
2023-12-31 $693.00M $N/A $12.06B $12.13B $-70.00M
2022-12-31 $706.00M $N/A $10.96B $11.85B $-892.00M
2021-12-31 $737.00M $N/A $10.68B $12.19B $-1.51B
2020-12-31 $12.00M $N/A $10.11B $4.62B $5.49B
2019-12-31 $319.00M $N/A $10.55B $3.51B $7.04B
2018-12-31 $244.00M $N/A $10.49B $4.15B $6.35B
2017-12-31 $N/A $N/A $N/A $N/A $N/A

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
May 06, 2025 N/A N/A N/A N/A N/A N/A
May 06, 2025 N/A N/A N/A N/A N/A N/A
May 05, 2025 N/A N/A N/A N/A N/A N/A
May 05, 2025 N/A N/A N/A N/A N/A N/A
May 05, 2025 N/A N/A N/A N/A N/A N/A
May 05, 2025 N/A N/A N/A N/A N/A N/A

Watchlist

0

No stocks in watchlist